(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Instructions to Help a Friend or family member Determined to have Cellular breakdown in the lungs - 2ACA subsidies latest: Making sense of what's happening with health care after Republicans revolt, forcing a vote on funding extension
- 3Impact of NIH funding reductions felt in cancer and infectious disease trials
- 4CDC changes kids' vaccine schedule, removing universal recommendation for some shots
- 5Experiences in Natural life Protection: Individual Progressives' Excursions
- Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
- 'I was diagnosed with incurable brain cancer on holiday'
- The 10 Most Persuasive Forerunners in Innovation
- Israel kidnaps PIJ terrorist in covert op. in Hamas-controlled Gaza in pursuit of Ran Gvili
- Why are malnutrition deaths soaring in America?
- Blake Lively's sexual harassment claims against Justin Baldoni dismissed. Where the case stands now.
- A Past filled with Old Civilizations: The World's Most established Societies
- Here's what the Artemis 2 astronauts will be doing on each day of NASA's historic moon mission
- Al-Sharaa denies he called for 80% of Syrians to return from Germany
